Articles on Ebixa (memantine) from NPS RADARArticles on Ebixa (memantine) from NPS RADAR

Title Content Type Date Description
Erratum: Memantine (Ebixa) for dementia in moderately severe Alzheimer’s disease Professional publication - NPS RADAR - Brief item 2008-12-01 00:00:00 Information on the dose titration of memantine contained in Table 1 of the NPS RADAR review of memantine in the August issue was incorrect. The dose for the tablet formulation was correct but the dose for the oral solution was mistakenly halved.
Memantine (Ebixa) for moderately severe Alzheimer’s disease Professional publication - NPS RADAR - Review 2008-08-01 00:00:00 Memantine has a different mechanism of action to the cholinesterase inhibitors. It provides modest improvements in cognitive, psychological and behavioural functioning, but the clinical importance of these improvements is yet to be established.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-30 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.